ReviewBreathe (Sheffield, England)2024
Stage III NSCLC treatment options: too many choices.
Review in Breathe (Sheffield, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Neo-DIANA: descriptive results of a prematurely terminated phase II trial of neoadjuvant atezolizumab, chemotherapy and bevacizumab in resectable EGFR-mutated NSCLC.Translational lung cancer research · 2026Article
- Real-World Insights into Stage I-III Non-Small Cell Lung Cancer in Spain in the Pre-Immunotherapy Era Using AI Techniques: The IntellyLUNG Study.Life (Basel, Switzerland) · 2026Article
- Targeting non-small cell lung cancer: Molecular mechanisms and clinical studies (Review).Oncology letters · 2026Review
- Comparative Prognostic Performance of CARWL and Naples Prognostic Score in Stage IIIC Non-Small Cell Lung Cancer Treated with Definitive Chemoradiotherapy.Medical sciences (Basel, Switzerland) · 2026Article
- ERS Congress 2025: highlights from the Thoracic Oncology Assembly.ERJ open research · 2026Article
- Subgroup and Prognostic Factor Analysis in T4 Lung Cancer Based on the 9th Tumour-Node-Metastasis Classification.Interdisciplinary cardiovascular and thoracic surgery · 2025Article
- Directions of Immunotherapy for Non-Small-Cell Lung Cancer Treatment: Past, Present and Possible Future.International journal of molecular sciences · 2025Review
- Robot-assisted thoracic surgery (RATS): learning curve and outcomes for 200 consecutive pulmonary lobectomies in a Norwegian hospital.Journal of thoracic disease · 2025Article
- Surgical consensus for screening, diagnosis, staging, multimodal management and surveillance of early-stage resectable non-small cell lung cancer (NSCLC) in Malaysia.Translational lung cancer research · 2025Review
- ERS Congress 2024: highlights from the Thoracic Oncology Assembly.ERJ open research · 2025Article
- Thoracic Malignancies: From Prevention and Diagnosis to Late Stages.Life (Basel, Switzerland) · 2025Article
- Radiomic approach to support multidisciplinary tumor board decision-making in locally advanced non-small cell lung cancer.Frontiers in oncology · 2025Article
- Real-World Data on Stage III Non-Small Cell Lung Cancer in Vietnam.Oncology research · 2025Article
- Tumor heterogeneity assessment using single-cell RNA sequencing (scRNA-seq): applications in lung cancer for diagnosis and treatment.Frontiers in immunology · 2025Review
- The Ligurian Experience in the Management of Lung Cancer: Organizational Models and New Perspectives.Healthcare (Basel, Switzerland) · 2024Article
- Lung cancer: an update on the multidisciplinary approach from screening to palliative care.Breathe (Sheffield, England) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stage III nonsmall cell lung cancer (NSCLC) represents a wide range of tumour (T1 to T4) and nodal (N0 to N3) components, requiring variable management and a multidisciplinary approach. Recent advancements in minimally invasive techniques, molecular biology and novel drug discoveries have accelerated the refinement of stage III NSCLC management. The latest developments in staging include the forthcoming update of the nodal component in the 9th TNM (tumour-node-metastasis) edition, which emphasises the critical role for endobronchial ultrasonography in mediastinal staging. Recent treatment developments include the use of immunotherapy and targeted molecular therapy in both the neoadjuvant and adjuvant setting, either in combination with other modalities or used alone as consolidation. Surgical and radiotherapy advancements have further enhanced patient outcomes. These developments have significantly improved the prognosis for patients with stage III NSCLC. Fast-changing recommendations have also brought about a challenge, with clinicians facing a number of options to choose from. Therefore, a multimodal approach by a multidisciplinary team has become even more crucial in managing stage III NSCLC.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.